Lisa Carey, MD, of the University of North Carolina, discusses heterogeneity, treatment response, and outcome in HER2-positive breast cancer.
Shailender Bhatia, MD, of the Fred Hutchinson Cancer Center, discusses his paper on interleukin-12 DNA and regression of Merkel cell tumors (Abstract 504).
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, discusses the ESMO initiative to make cancer drugs affordable.
Jean-Yves Douillard, MD, PhD, of Centre R Gauducheau, reviews new clinical trials and data on systemic and radiation treatment of small cell lung cancer.
Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses the results of this study, which could well change the treatment paradigm in patients with previously treated metastatic renal cell carcinoma (Abstract 3LBA).
Incoming ECCO President, Peter L. J. Naredi, MD, PhD, of the University of Gothenburg, discusses his upcoming year as the new ECCO President, his vision for the organization, and his views on cancer treatment today.
